Virtual Library

Start Your Search

Mahyar Lavae-Mokthari



Author of

  • +

    EP1.12 - Small Cell Lung Cancer/NET (ID 202)

    • Event: WCLC 2019
    • Type: E-Poster Viewing in the Exhibit Hall
    • Track: Small Cell Lung Cancer/NET
    • Presentations: 1
    • Now Available
    • Moderators:
    • Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall
    • +

      EP1.12-33 - Prognostic Analysis of Surgery vs. Conservative Therapy with Chemotherapy in Stage of Limited Disease Small Cell Lung Cancer  (Now Available) (ID 2627)

      08:00 - 18:00  |  Author(s): Mahyar Lavae-Mokthari

      • Abstract
      • Slides

      Background

      The current standard of care for limited disease small-cell lung cancer (SCLC) consists of combination chemotherapy and thoracic radiotherapy during the early cycles of chemotherapy. Unfortunately, the prognosis is poor and the long-term survival is limited. The 5-year overall survival rate of SCLC reaches 5%. Furthermore, the role of surgery as a part of multimodality treatment with curative intent remains controversial. Here we investigate the long-term survival benefit of patients with limited disease SCLC following surgery combined with chemotherapy compared to those without surgery.

      Method

      In this retrospective analysis was analyzed all the patients with limited disease small-cell lung cancer from our hospital database. Between January 2010 and May 2015, all patients with limited disease small-cell lung cancer were retrospectively enrolled and data retrospectively analyzed. Patients were grouped for multimodality treatment with chemotherapy and surgery consisting of primary tumor resection and systematic lymph node dissection (Group 1) versus chemoradiotherapy alone (Group 2).

      Survival time was defined as the frame of the date of diagnosis to the time of death. Deaths from other causes are censored. The primary endpoint for this analysis was the survival time.

      Result

      A total of 47 patients were included. About 16 Patients received treatment in the main focus with surgery (group 1), 31 patients had treatment without surgical treatment (group 2).

      In group 1 with surgical treatment 4 patients of 16 died within the first 16 months.

      The minimal survival time was 13 months and the maximum was detected at 48 months. The median survival time was discovered at 13 months, the arithmetic mean was 23 months. The standard deviation from the mean was 3,94.

      In the group without surgery 11 patients of 31 died. In this group the minimal survival time was 1 month and the maximum survival time was determined at 43 months. The median survival time was founded at 10 months, the arithmetic mean at 17 month. The standard deviation from the mean was detected at 16,08.

      Conclusion

      One of the leading cause of death from cancer around the world is small cell lung cancer . The characteristics of rapid growth and early metastasis, is still an intractable problem for the treatment of small lung cancer. In addition only few patients are diagnosed in early stages, so that a surgical treatment can be considered.

      If we compare the patients who had surgical treatment with patients without surgery, we see that the group with surgical treatment seems to have a longer median survival time. The surgery seems to be safe and an important component of the multidisciplinary treatment.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.